N-methylbenzo[c][1,25]thiadiazol-4-amine | 66046-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻二唑类
• 英文名称: N-methylbenzo[c][1,25]thiadiazol-4-amine
• 英文别名: 4-methylaminobenzo-2,1,3-thiadiazole；benzo[1,2,5]thiadiazol-4-yl-methyl-amine；4-Methylamino-benzo-2,1,3-thiadiazol；N-methyl-2,1,3-benzothiadiazol-4-amine
• CAS: 66046-52-4；60045-71-8
• 化学式: C₇H₇N₃S
• 分子量: 165.219
• InChiKey: CRBPZRGRXLUUFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-methylbenzo[c][1,25]thiadiazol-4-amine 在 盐酸 、 双氧水 作用下， 以 乙腈 为溶剂， 以41%的产率得到5-chloro-4,7-dioxo-4,7-dihydrobenzo-2,1,3-thiadiazole
  参考文献：
  名称：

  在过氧化氢和盐酸的作用下，将4-取代的苯并-2,1,3-噻二唑转化为5-氯-4,7-二氧苯并-2,1,3-噻二唑

  摘要：

  DOI：

  10.1007/bf00475579
• 作为产物：
  描述：

  4-氨基-2,1,3-苯并噻二唑 、 硫酸二甲酯 在 碳酸氢钠 作用下， 反应 1.0h， 生成 N-methylbenzo[c][1,25]thiadiazol-4-amine
  参考文献：
  名称：

  Synthesis of certain quaternary derivatives in the aminophenol and benzo-2,1,3-thiadiazole series as potential radiation-protecting materials

  摘要：

  DOI：

  10.1007/bf00757982

文献信息

• Improved and General Manganese‐Catalyzed N‐Methylation of Aromatic Amines Using Methanol
  作者：Jacob Neumann、Saravanakumar Elangovan、Anke Spannenberg、Kathrin Junge、Matthias Beller

  DOI：10.1002/chem.201605218

  日期：2017.4.24

  A novel lutidine‐based manganese PNP‐pincer complex has been synthesized for the selective N‐methylation of aromatic amines with methanol. Using borrowing hydrogen methodology, a selection of differently functionalized aniline derivatives is selectively methylated in good yields.

  已经合成了一种新型的基于二甲基吡啶的锰PNP钳配合物，用于甲醇对芳香胺的选择性N-甲基化。使用借用氢方法学，可以以良好的收率选择性地选择不同功能化的苯胺衍生物。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080119457A1

  公开（公告）日：2008-05-22

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 31 , and R 41 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  公开了公式I的化合物和药用盐，其中A、Q1、Q2、Q3、R31和R41如本文所定义。公式I的化合物在治疗与细胞增殖相关的疾病和/或病况方面具有用途，如癌症、炎症、关节炎、血管生成等。还公开了包括本发明化合物的药物组合物以及使用这些化合物治疗上述病况的方法。
• Pyrimidine and Pyrazine Derivatives
  申请人：Huang He Kenneth

  公开号：US20080070930A1

  公开（公告）日：2008-03-20

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 0 , R 3 , R 7 , n, Q 1 , Q 2 , Y, and X 1 -X 3 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明揭示了I式化合物及其药学上可接受的盐，其中R0、R3、R7、n、Q1、Q2、Y和X1-X3如本文所定义。I式化合物在治疗与细胞增殖有关的疾病和/或病况（如癌症、炎症、关节炎、血管生成等）方面具有用途。本发明还揭示了包括本发明化合物的药物组合物和使用这些化合物治疗上述病况的方法。
• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Kubota Hideki

  公开号：US20080227785A1

  公开（公告）日：2008-09-18

  This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

  本发明涉及一种以BEC 1钾离子通道抑制剂作为活性成分的抗痴呆剂。已经证明，BEC 1钾离子通道抑制剂具有改善学习障碍的作用，并且作为预防或治疗剂是有用的，尤其是对于BEC 1钾离子通道与之相关的疾病，如痴呆症。例如，通过体内试验证实，BEC 1钾离子通道抑制剂具有改善学习障碍的作用。此外，还发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾离子通道抑制作用。
• Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives
  申请人：Huang He Kenneth

  公开号：US20080070918A1

  公开（公告）日：2008-03-20

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 3 , and R 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明涉及公式I的化合物和药学上可接受的盐，其中A、Q1、Q2、Q3、R3和R4的定义如本文所述。公式I的化合物在治疗与细胞增殖有关的疾病和/或情况，如癌症、炎症、关节炎、血管生成等方面具有用途。本发明还涉及包含本发明化合物的制药组合物以及使用这些化合物治疗上述疾病和情况的方法。